Key facts
- China's biotechnology sector is facing a critical shortage of laboratory monkeys.
- This scarcity is impacting research and development activities.
- The situation could hinder the overall growth of China's biotech industry.
China's rapidly expanding biotechnology sector is grappling with a significant shortage of laboratory monkeys, a crucial resource for preclinical drug testing and research. This scarcity is raising concerns about the industry's future growth and its ability to innovate at a pace comparable to global competitors.
The demand for non-human primates, particularly cynomolgus monkeys, has surged in China as the country aims to become a global leader in biopharmaceutical development. However, factors such as increased domestic research, a decline in imports, and potential supply chain disruptions have led to a critical deficit.
This shortage could delay the development of new drugs and therapies, potentially impacting clinical trials and the overall competitiveness of Chinese biotech firms on the international stage. The situation underscores the complex challenges faced by emerging biotech hubs in securing essential research materials.